Daiichi Sankyo (DSNKY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec24

Daiichi Sankyo and Merck Lung Cancer Clinical Trial Update

16:32

Dec22

ENHERTU® Launched Phase III Clinical Trial for Endometrial Cancer

07:32

ENHERTU Receives FDA Breakthrough Therapy Designation

07:32

Dec18

EMA Validates DATROWAY Marketing Authorization Application

07:32

Dec15

AstraZeneca and Daiichi Sankyo Receive FDA Approval for ENHERTU® in Combination with Pertuzumab for First-Line Treatment of HER2-Positive Breast Cancer

21:57

AstraZeneca's Enhertu Approved for First-Line HER2-Positive Metastatic Breast Cancer Treatment

20:38

Schedules & Filings

Schedules

Filings

Jan30

Earning Release(EST)

FY2026 Q3 Earning Release

Oct31

Earning Release(EST)

FY2026 Q2 Earning Release (USD) Revenue 3.369 B, Net Income 304.88 M, EPS 0.1646

Sep30

Distribution Plan(EST)

Cash dividend 0.2698 USD

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change